Eli Lilly reports results from Phase 3 monarchE trial

Eli Lilly (LLY) and Company announced results from the primary overall survival analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy reduced the risk of death by 15.8% versus ET alone and resulted in sustained long-term improvements in invasive disease-free survival and distant relapse-free survival, in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer. These results were published in the Annals of Oncology and will be shared in a late-breaking oral presentation at the ESMO Annual Meeting today, Friday, October 17, at 2:50 PM CEST/08:50 AM ET in Berlin, Germany. These data are being submitted to regulatory health authorities globally.